Although some clinicians do not recommend the use of tacrolimus for SOT recipients with symptomatic COVID-19, a study on liver transplant patients showed that tacrolimus has more protective potential than CyA, mTOR inhibitors, and MPA [75]. Here, MTOR is linked to COVID-19.